Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21460190 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17082823 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18663772 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL21460143 | 0.97 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16893316 | 0.86 | — | — | |
| SCHEMBL25413280 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL904296 | 0.83 | — | — | |
| SCHEMBL22795640 | 0.83 | — | — | |
| SCHEMBL12350249 | 0.83 | — | — | |
| SCHEMBL12350240 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143875-B1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2020-05-27 | — | — | EP | disclosed |
| EP-2957295-B1 | METHOD FOR TREATING ALZHEIMER'S DISEASE USING PHARMACOLOGICAL CHAPERONES TO INCREASE THE ACTIVITY OF GANGLIOSIDASES | AMICUS THERAPEUTICS INC (US) | 2017-08-02 | — | — | EP | disclosed |